Akari Therapeutics Plc
For the period ended Jun 30, 2024. Filed Aug 19, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 19, 2024
AKTX$7.13-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| (In thousands) | 2024 | 2023 |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(13,124) | $(2,999) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 13 | 2 |
| Share-based compensation | 741 | 541 |
| Change in fair value of warrant liability | (498) | (6,147) |
| Foreign currency exchange losses (gains) | 280 | (34) |
| Change in assets and liabilities: | ||
| Prepaid expenses and other current assets | 702 | (269) |
| Accounts payable and accrued expenses | 2,948 | (668) |
| Net cash used in operating activities | (8,938) | (9,574) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from issuance of shares, net of issuance costs | 8,820 | 3,502 |
| Proceeds from issuance of convertible notes | 1,000 | — |
| Proceeds from employee vesting of restricted shares | 3 | 1 |
| Payments on short-term financing arrangement | (546) | — |
| Net cash provided by financing activities | 9,277 | 3,503 |
| Effect of exchange rates on cash | (7) | 2 |
| Net increase (decrease) in cash | 332 | (6,069) |
| Cash at beginning of period | 3,845 | 13,250 |
| Cash at end of period | $4,177 | $7,181 |
| SUPPLEMENTAL DISCLOSURES OF NONCASH ACTIVITIES: | ||
| Financing costs in accrued expenses | $205 | $— |
| Non-cash seller-financed purchases | $1,105 | $— |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFO: | ||
| Cash paid during the period for interest | $51 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.